Novo Nordisk Battles Declining Wegovy Sales and Investor Concerns
The pharmaceutical giant faces mounting competition from Eli Lilly's Zepbound and compounded semaglutide products, while its shares plummet 25% in March 2025.
- Novo Nordisk's shares have dropped 25% in March 2025, marking their steepest monthly decline since 2002, as investor confidence wanes.
- Eli Lilly's Zepbound has surpassed Wegovy in both clinical trial results and weekly U.S. prescriptions, intensifying market competition.
- The FDA's declaration of Wegovy's shortage ending requires compounding pharmacies to cease production of semaglutide alternatives by May 22, 2025.
- Novo Nordisk has launched legal actions against compounders and expanded its savings program, offering Wegovy at a reduced price of $499 per month.
- The company has raised safety concerns about compounded semaglutide products, citing impurities and unapproved substances in some alternatives.
CNBC 
